Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Chandler, AZ
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Phoenix, AZ
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Walnut Creek, CA
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Coral Gables, FL
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Coral Gables, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Debary, FL
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Debary, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Miami, FL
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
South Miami, FL
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Newton, KA
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Newton, KA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Kansas City, MO
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Cary, NC
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Cary, NC
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Akron, OH
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Cleveland, OH
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Dayton, OH
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
New Braunfels, TX
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
New Braunfels, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
South Jordan, UT
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
South Jordan, UT
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated:  11/11/2015
Clinical Research Facility
mi
from
Richmond, VA
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older
Status: Enrolling
Updated: 11/11/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Colorado
mi
from
Denver, CO
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Yale University
mi
from
New Haven, CT
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Florida
mi
from
Gainsville, FL
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Florida
mi
from
Gainsville, FL
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Tampa General Hospital
mi
from
Tampa, FL
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Chicago
mi
from
Chicago, IL
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Michigan
mi
from
Ann Arbor, MI
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Henry Ford Health Care System
mi
from
Detroit, MI
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Henry Ford Health Care System
mi
from
Detroit, MI
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Columbia University
mi
from
New York, NY
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Medical University of South Carolina
mi
from
Charleston, SC
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Methodist Healthcare System
mi
from
San Antonio, TX
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Methodist Healthcare System
mi
from
San Antonio, TX
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Utah
mi
from
Salt Lake City, UT
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Univ of Washington
mi
from
Seattle, WA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Emory University
mi
from
Atlanta, GA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Northwestern University Medical Center
mi
from
Chicago, IL
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Northwestern University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Massachusetts
mi
from
Worcester, MA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Massachusetts
mi
from
Worcester, MA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Nebraska
mi
from
Omaha, NE
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Nebraska
mi
from
Omaha, NE
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials